Indication

Follicular and Aggressive B-cell Lymphoma

1 clinical trial

1 product

Clinical trial

A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma

Status: Completed, Estimated PCD: 2018-07-11

Product